1. European Medicines Agency. First gene therapy to treat severe haemophilia A. https://www.ema.europa.eu/en/news/first-gene-therapy-treat-severe-haemophilia (2022). Accessed 1 Mar 2023.
2. Food and Drug Administration. FDA approves first gene therapy for adults with severe hemophilia A. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-adults-severe-hemophilia (2023). Accessed 1 Sep 2023.
3. Food and Drug Administration. FDA approves first gene therapy to treat adults with hemophilia B. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b (2022). Accessed 1 Mar 2023.
4. CSL Behring. Press release: European Medicines Agency commences review of novel gene therapy candidate etranacogene dezaparvovec for people with hemophilia B. https://newsroom.csl.com/2022-03-28-European-Medicines-Agency-Commences-Review-of-Novel-Gene-Therapy-Candidate-Etranacogene-Dezaparvovec-for-People-with-Hemophilia-B (2022). Accessed 1 Mar 2023.
5. European Medicines Agency. First gene therapy to treat haemophilia B. https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b(2022). Accessed 1 Mar 2023.